Do all chemotherapies have equal long-term heart risk?
Study of 28,000 childhood cancer survivors finds important differences
- Date:
- January 31, 2019
- Source:
- University of Texas Health Science Center at San Antonio
- Summary:
- Different chemotherapy drugs were associated with varying degrees of long-term risk of cardiomyopathy in survivors of childhood cancers, according to a new study.
- Share:
In long-term survivors of childhood cancer, cardiovascular disease is a leading cause of early death from non-cancer causes. In a new study, published Jan. 31 in JAMA Oncology, researchers compared four chemotherapy drugs with development of cardiomyopathy (abnormal heart muscle with impaired function) years after treatment.
"Exposure to anthracycline chemotherapies, such as doxorubicin, has long been associated with an increased risk of cardiovascular disease in long-term childhood cancer survivors," said Gregory Aune, M.D., Ph.D., of UT Health San Antonio. "Previously, it was assumed that exposure to any member of the anthracycline class carried the same risk of late cardiovascular complications. By studying the outcomes of over 28,000 long-term survivors in the U.S. and Europe, this research indicates that exposure to different anthracyclines results in variable long-term cardiovascular risk. In the future, it will be important to take these differences into account when screening long-term survivors for cardiovascular complications and in the development of modern treatment regimens."
The drug daunorubicin was associated with decreased cardiomyopathy risk when compared to doxorubicin, the study showed. Mitoxantrone, another chemotherapy, appeared to have greater long-term cardiomyopathy risk than was previously estimated.
"The past several decades have been focused on devising combinations of drugs that work best for curing patients," said Gail Tomlinson, M.D., Ph.D., professor of pediatrics, division director of pediatric hematology-oncology, and holder of the Greehey Distinguished Chair in Genetics and Cancer at UT Health San Antonio. "This has been a highly successful process with a substantial increase in survival for most cancer types. Now with so many survivors alive many years from their original cancer, it is imperative to fine-tune protocols based on the goal of minimizing late effects."
Dr. Aune, assistant professor of pediatric hematology-oncology at UT Health San Antonio and an investigator with the university's Greehey Children's Cancer Research Institute, assisted in the study design and review. Co-authors are from the Netherlands; the Fred Hutchinson Cancer Research Center in Seattle; St. Jude Children's Research Hospital in Memphis, Tenn.; the Duke University School of Medicine; and the University of Washington, Seattle.
Story Source:
Materials provided by University of Texas Health Science Center at San Antonio. Note: Content may be edited for style and length.
Journal Reference:
- Elizabeth A. M. Feijen, Wendy M. Leisenring, Kayla L. Stratton, Kirsten K. Ness, Helena J. H. van der Pal, Elvira C. van Dalen, Gregory T. Armstrong, Gregory J. Aune, Daniel M. Green, Melissa M. Hudson, Jacqueline Loonen, Kevin C. Oeffinger, Leslie L. Robison, Yutaka Yasui, Leontien C. M. Kremer, Eric J. Chow. Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity. JAMA Oncology, 2019; DOI: 10.1001/jamaoncol.2018.6634
Cite This Page: